1. Home
  2. KBDC vs CSTL Comparison

KBDC vs CSTL Comparison

Compare KBDC & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kayne Anderson BDC Inc.

KBDC

Kayne Anderson BDC Inc.

HOLD

Current Price

$14.52

Market Cap

1.0B

Sector

N/A

ML Signal

HOLD

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$41.91

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KBDC
CSTL
Founded
2021
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
KBDC
CSTL
Price
$14.52
$41.91
Analyst Decision
Buy
Strong Buy
Analyst Count
5
6
Target Price
$15.80
$46.00
AVG Volume (30 Days)
319.3K
323.5K
Earning Date
03-02-2026
02-26-2026
Dividend Yield
13.06%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$343,530,000.00
Revenue This Year
$193.84
$2.54
Revenue Next Year
$9.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
10.15
52 Week Low
$13.06
$14.59
52 Week High
$17.99
$43.01

Technical Indicators

Market Signals
Indicator
KBDC
CSTL
Relative Strength Index (RSI) 44.99 66.08
Support Level $14.47 $39.74
Resistance Level $14.93 $43.01
Average True Range (ATR) 0.36 1.72
MACD 0.00 0.06
Stochastic Oscillator 36.74 80.68

Price Performance

Historical Comparison
KBDC
CSTL

About KBDC Kayne Anderson BDC Inc.

Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Share on Social Networks: